

Editors: John Crocker, David Burnett

Reviews Editor: Claire Lewis

Technical Editor: Andrea Horgan

Editorial Assistant: Amanda Lugg

Editorial Board

M Abrahamson (Lund)
D Buttle (Sheffield)
M Derenzini (Bologna)
M Fagerhol (Oslo)
C Fegan (Birmingham)
P Hall (Dundee)
L Harvath (Bethesda)
C S Herrington (Liverpool)
E Hillhouse (Warwick)

J Jankowski (Birmingham)
D B Jones (Southampton)
N Lemoine (London)
A S-Y Leong (Adelaide)
T J Ley (St Louis)
N Mamaev (St Petersburg)
J O'D McGee (Oxford)
A Morris (Warwick)
T Murphy (Buffalo)

D Ploton (Reims)
P Quirke (Leeds)
D Ramsden (Birmingham)
P Schofield (Cambridge)
H B F Sewell (Nottingham)
J Waters (Birmingham)
L S Young (Birmingham)
Editor, *BMJ*
Editor, *JCP*

MP
MOLECULAR
PATHOLOGY

Notes to Contributors

Manuscripts should be sent to the Editors, *Molecular Pathology*, Department of Histopathology, Birmingham Heartlands Hospital, Bordesley Green East, Birmingham B9 5SS (tel: 0121 773 1161; fax: 0121 773 1182). Receipt of manuscripts will be acknowledged by the editorial office.

Submission of a paper will be held to imply that it contains original work not being offered elsewhere or published previously. Manuscripts should be prepared in accordance with the Vancouver style. The Editors retain the right to shorten the article or make changes to conform with style and to improve clarity. All authors must sign the copyright form after acceptance.

General

● Authors must submit three copies of the original manuscript typed in double line space. Revised manuscripts should be submitted as printed copy and on disk. A guide to submitting an article on disk will be sent when requesting a revision or on notification of an acceptance. Authors should not submit the original paper on disk.

● The names of the authors, with initials or one forename, should be followed by the name of the institution where the work was carried out. An indication of the position held by each author should be given in an accompanying letter to the Editors, and manuscripts should bear the name of one author to whom correspondence should be addressed. If available, a fax number and an e-mail address should be supplied.

● Authors should include the names and addresses of four experts whom the authors consider suitable to peer review their work.

● The number of authors should be kept to a minimum and should include only those who have made a contribution to the research; justification should be made for more than five authors. Acknowledgments should be limited to workers whose courtesy or assistance has extended beyond their paid work, and to supporting organisations.

● Authors should provide up to four keywords/phrases for the index.

● All measurements must be in SI units apart from blood pressure measurements, which should be in mmHg, and drugs in metric units.

● Abbreviations should be used rarely and should be preceded by the words in full before the first appearance.

● In the statistical analysis of data 95% confidence intervals should be used where appropriate.

● No free offprints will be provided; reprints may be ordered when the proof is returned.

Original articles

● Papers should report original research of relevance to the understanding and practice of molecular pathology. They should be written in the standard form: abstract; introduction; methods; and discussion.

● The journal uses a structured form of abstract in the interests of clarity. This should be short (no more than 250 words) and include four headings: *Aims*—the main purpose of the study; *Methods*—what was done, and with what material; *Results*—the most important results illustrated by numerical data but not p values; and *Conclusions*—the implications and relevance of the results.

Leaders/Editorials

● Leaders and Editorials are published by editorial invitation.

Short reports

● Single case reports of outstanding interest or clinical relevance, short technical notes, and brief investigative studies are welcomed and usually published in the form of a Short Technical report.

● Length must not exceed 1500 words, including an unstructured abstract of less than 150 words, up to two figures or tables (or one of each) and up to 10 references. If more illustrations are required the text must be reduced accordingly.

Letters

● Letters must be typed in double line spacing, should normally be no more than 500 words, have no more than five references, and must be signed by all authors. Two copies should be provided.

Tables and figures

Tables should be presented separately in double line spacing without ruled lines; when presented on disk they should be in a separate file from the text.

● Letters and other marks which are to appear on the face of a photomicrograph should be made on a photocopy; they will be added in the Journal style in the editorial office when the manuscript is accepted.

● The staining technique used should be stated. Magnifications should be given for electron micrographs but not for light micrographs except in cases where this is important.

● Photographs and photomicrographs should be on glossy paper for half tone reproduction. The printing process requires that prints are unmounted and unbacked, and of high quality, with full tonal scale. Illustrations that will not reproduce well will be returned and this may delay publication. Areas in which tissue does not appear ("background") should be as near white as possible. Three sets of prints must be supplied with each manuscript. Only salient features should be included to preserve detail.

● Colour reproduction of figures in papers is encouraged and is heavily subsidised by the Journal. Advice on costs and material to be submitted for colour work should be sought from the editorial office.

● If any tables or illustrations submitted have been published elsewhere, written consent to republication should be obtained by the author from the copyright holder (usually the publisher) and the authors. A copy of the letter giving consent must be included.

References

● References must be numbered in the order they appear in the text, include all information (Vancouver style) and be identified by arabic numerals in brackets, eg [1] [2].

● Abstracts, information from manuscripts not yet accepted, or personal communications may be cited only in the text and not included in the references. References are not checked by us; authors must verify references against the original documents before submitting the article.

NOTICE TO ADVERTISERS Applications for advertisement space and for rates should be addressed to the Advertisement Manager, *Molecular Pathology*, BMJ Publishing Group, BMA House, Tavistock Square, London WC1H 9JR.

NOTICE TO SUBSCRIBERS The *Molecular Pathology* is published bimonthly. The annual subscription rates are £88.00; USA \$136.00. Orders should be sent to The Subscription Manager, *Molecular Pathology*, BMJ Publishing Group, BMA House, Tavistock Square, London WC1H 9JR. Subscribers may pay for their subscriptions by Access, Visa, or American Express by quoting on their order the credit or charge card preferred together with the appropriate personal account number and expiry date of the card. Orders can also be placed with any leading subscription agent or bookseller. (For the convenience of readers in the USA subscription orders, with or without payment, may also be sent to the *British Medical Journal*, Box 408, Franklin, MA 02038, USA. All enquiries, however, must be addressed to the publisher in London.) All enquiries regarding air mail

rates and single copies already published should be addressed to the publisher in London.

COPYRIGHT © 1997 *Journal of Clinical Pathology*. This publication is copyright under the Berne Convention and the International Copyright Convention. All rights reserved. Apart from any relaxations permitted under national copyright laws, no part of this publication may be reproduced, stored in a retrieval system or transmitted in any form or by any means without the prior permission of the copyright owners. Permission is not, however, required to copy abstracts of papers or of articles on condition that a full reference to the source is shown. Multiple copying of the contents of the publication without permission is always illegal.

Periodicals postage paid at Rahway NJ. Postmaster: send address changes to: *Journal of Clinical Pathology*, BMJ Publishing Group, PO Box 590A, Kennebunkport, ME 04046, USA.

Cover illustration: Human metaphase chromosomes showing BrdU replication bands and mapping of a T-cell antigen receptor gene, the Zeta gene. This gene maps to the 1q23.1 band adjacent to the 1q heterochromatic block. This gene locus, seen as red dots on each chromatid, was identified by fluorescence in situ hybridisation (FISH), using a digoxigenin labelled probe. (See: Hultén *et al.* Does junk DNA regulate gene expression in humans? *J Clin Pathol: Mol Pathol* 1995;48:M118-23.)

Molecular Pathology is indexed in *Index Medicus* and Current Contents.

Contents lists and Instructions for Authors are now available on the Internet: <http://www.bmj.com/bmj>
Published by BMJ Publishing Group and printed in England on acid free paper by Latimer Trend & Co., Plymouth
ISSN 1355-2910.

Edition of the *Journal of Clinical Pathology*

clearly demonstrated.³² Studies establishing the role of the NISH assay in predicting the progression of CIN to cervical cancer is awaited. The combined preservation of morphology with the physical state of HPV DNA in cervical cancers permits researchers access to a powerful investigative technique to pursue research into cervical carcinogenesis.

- 1 Parkin DM, Muir CS. Cancer incidence in five continents. Comparability and quality of data. *LARC Sci Publ* 1992;120:45-173.
- 2 Brinton LA. Epidemiology of cervical cancer—overview. *LARC Sci Publ* 1992;119:3-23.
- 3 Herrington CS. HPV and cervical neoplasia. I. Classification, virology, pathology, and epidemiology. *J Clin Pathol* 1994;47:1066-72.
- 4 Bosch FX, Manos MM, Muboz N, Sherman M, Jansen AM, Petro J, et al. Prevalence of HPV in cervical cancer: a worldwide perspective. *J Natl Cancer Inst* 1995;87:796-802.
- 5 Lörincz AT, Reid R, Jensen AB, Greenberg MD, Lancaster WD, Kurman RJ. HPV infection of the cervix: relative risk associations of 15 common anogenital types. *Obstet Gynecol* 1992;79:328-37.
- 6 Sherman ME, Schiffman MH, Lörincz AT, Manos MM, Scott DR, Kurman RJ, et al. Towards objective quality assurance in cervical cytopathology: correlation of cytopathologic diagnoses with detection of high-risk HPV types. *Am J Clin Pathol* 1994;102:182-7.
- 7 Koutsky LA, Holmes KK, Critchlow CW, Stevens CE, Paavonen J, Beckman AM, et al. A cohort study of the risk of CIN grade 2 or 3 in relation to papillomavirus infection. *N Engl J Med* 1992;327:1272-8.
- 8 Syrjänen KJ. Natural history of genital HPV infections. *Papillomavirus Report* 1990;1:1-4.
- 9 Woodman CBJ, Rollason T, Ellis J, Tierney R, Wilson S, Young L. HPV infection and risk of progression of epithelial abnormalities of the cervix. *Br J Cancer* 1996;73:553-6.
- 10 Campion MJ, McCance DJ, Cuzick J, Singer A. Progressive potential of mild cervical atypia: prospective cytological, colposcopic, and virological study. *Lancet* 1986;iii:237-40.
- 11 Ho GYF, Burk RD, Klein S, Kadish AS, Chang CJ, Palan P, et al. Persistent genital HPV infection as a risk factor for persistent cervical dysplasia. *J Natl Cancer Inst* 1995;87:1365-71.
- 12 Chua K-L, Hjerpe A. Persistence of HPV infections preceding cervical carcinoma. *Cancer* 1996;77:12-7.
- 13 Walboomers JMM, de Roda Husman A-M, Snijders PJF, Stel HV, Risse EKJ, Helmerhorst TJM, et al. HPV in false negative archival cervical smears: implications for screening for cervical cancer. *J Clin Pathol* 1995;48:728-32.
- 14 Herrington CS. Control of HPV replication: implications for squamous neoplasia [editorial]. *J Pathol* 1996;178:237-8.
- 15 Lörincz A. Hybrid capture™ method for detection of HPV DNA in clinical specimens. *Papillomavirus Report* 1996;7:1-5.
- 16 Herrington CS. HPV and cervical neoplasia. II. Interaction of HPV with other factors. *J Clin Pathol* 1995;48:1-6.
- 17 Cooper K, Herrington CS, Graham AK, Evans MF, McGee JO'D. In situ human papillomavirus (HPV) genotyping of cervical intraepithelial neoplasia in South African and British patients: Evidence for putative HPV integration in vivo. *J Clin Pathol* 1991;44:400-5.
- 18 Cooper K, Herrington CS, Graham AK, Evans MF, McGee JO'D. In situ evidence for HPV 16, 18, 33 integration in cervical squamous cell cancer in Britain and South Africa. *J Clin Pathol* 1991;44:406-9.
- 19 Cooper K, Herrington CS, Stickland JE, Evans MF, McGee JO'D. Episomal and integrated human papilloma virus in cervical neoplasia shown by non-isotopic in situ hybridisation. *J Clin Pathol* 1991;44:990-6.
- 20 Lehn H, Villa LL, Marziona F, Hilgarth M, Hillemans HG, Sauer G. Physical state and biological activity of HPV genomes in precancerous lesions of female genital tract. *J Gen Virol* 1988;69:187-96.
- 21 DiLuca D, Monini P, Rotola A, Savioli A, Cassai E. Episomal HPV isolated from a cervical carcinoma presents a partial duplication of the early region. *Virus Res* 1989;14:49-56.
- 22 Shirasawa H, Tomita Y, Kubota K, Kasai T, Sekiya S, Takamizawa H, et al. Detection of HPV type 16 DNA and evidence for integration into the cell DNA in cervical dysplasia. *J Gen Virol* 1986;67:2011-5.
- 23 Berumen J, Unger ER, Casas L, Figueroa P. Amplification of HPV types 16 and 18 in invasive cervical cancer. *Hum Pathol* 1995;26:676-81.
- 24 Kataja V, Syrjänen K, Mantyjarvi R, Vayrynen M, Syrjänen S, Saarikowski S, et al. Prospective follow up of cervical HPV infections: life table analysis of histopathological, cytological and colposcopic data. *Eur J Epidemiol* 1989;5:1-7.
- 25 Kataja V, Syrjänen K, Syrjänen S, Mantyjarvi R, Yliskowski M, Saarikowski S, et al. Prospective follow up of genital HPV infections: life table analysis of HPV typing data. *Eur J Epidemiol* 1990;6:9-14.
- 26 Vousden KH, Wrede D, Crook T. HPV oncoprotein function: releasing the brakes on cell growth control. *Papillomavirus Report* 1991;2:1-3.
- 27 Choo KB, Pan CC, Han SH. Integration of HPV 16 into cellular DNA of cervical carcinomas: preferential deletion of the E2 gene and invariable retention of the long control region and the E6/E7 ORFs. *Virology* 1987;161:259-61.
- 28 Schwarz E, Freese UK, Gissmann L, Mayer W, Roggenbuck B, Stremlau A, et al. Structure and transcription of HPV sequences in cervical carcinoma cells [letter]. *Nature* 1985;314:111.
- 29 Matlaszewski G, Osborn K, Banks L, Stanley M, Crawford L. Transformation of primary human fibroblast cells with HPV type 16 DNA and EJ-ras. *Int J Cancer* 1988;42:232-8.
- 30 Werness BA, Levine AJ, Howley PM. Association of HPV types 16 and 18 E6 proteins with p53. *Science* 1990;248:76-9.
- 31 Dyson M, Howley PM, Munger K, Harlow E. The HPV 16 E7 oncoprotein is able to bind to the retinoblastoma gene product. *Science* 1989;243:934-7.
- 32 Unger ER, Vernon SD, Thoms WW, Nisenbaum R, Spann CO, Horowitz IR, et al. HPV and disease-free survival in FIGO stage Ib cervical cancer. *J Infect Dis* 1995;172:1184-90.
- 33 Kristiansen E, Jenkins A, Holm R. Coexistence of episomal and integrated HPV 16 DNA in squamous cell carcinoma of the cervix. *J Clin Pathol* 1994;47:253-6.
- 34 Das BC, Sharma JK, Golapkrishna V, Luthra UK. Analysis by PCR of the physical state of HPV type 16 DNA in cervical preneoplastic and neoplastic lesions. *J Gen Virol* 1992;73:2327-36.
- 35 Cooper K. Non-isotopic in situ hybridisation in the detection of integrated HPV 16/18 in cervical cancers [letter]. *Hum Pathol* 1996;27:745.
- 36 Cooper K, Herrington CS, Lo E S-F, Evans MF, McGee JO'D. Integration of HPV types 16 and 18 in cervical adenocarcinoma. *J Clin Pathol* 1992;45:382-4.
- 37 Herrington CS, Graham AK, McGee JO'D. Interphase cytogenetics III: Increased sensitivity and flexibility of digoxigenin labelled DNA probes for HPV detection in cervical biopsies and cell lines. *J Clin Pathol* 1991;44:33-8.

Molecular Pathology: what's in a name?

This issue takes us into our third year. Our change of name is not merely cosmetic; our Editorial Board were in accord that the aims and content of the journal would be represented better by the exclusion of the word "clinical" from our title. This does not mean that we do not want to publish material with a clinical emphasis. Our ethos has always been to supplement the content of the *Journal of Clinical Pathology* with papers and reviews that include pure science which furthers our understanding of disease mechanisms. *Molecular Pathology* is, therefore, a title which represents accurately the aims and content of this journal.

After only two volumes, *Molecular Pathology* has over 2000 institutional subscribers worldwide and a combined (with *Journal of Clinical Pathology*) impact factor of 1.607. *Molecular Pathology* is indexed in *Index Medicus* and *Current Contents*. This is very creditable for so young a publication and indicates that *Molecular Pathology* is being read and cited by many of our co-workers. We hope that you will continue to support and enjoy *Molecular Pathology* in the years to come.

With all good wishes for 1997.

John Crocker and David Burnett

Instructions for Authors

Papers for publication should be sent to the Editors, *Molecular Pathology*, Department of Histopathology, Birmingham Heartlands Hospital, Bordesley Green East, Birmingham B9 5SS (tel: 0121 773 1161; fax: 0121 773 1182). Receipt of manuscripts will be acknowledged by the editorial office.

Submission of a paper will be held to imply that it contains original work not being offered elsewhere or published previously. Manuscripts should be prepared in accordance with the Vancouver style.¹ The Editors retain the right to shorten the article or make changes to conform with style and to improve clarity. All authors must sign the copyright form after acceptance.

Failure to adhere to any of these instructions may result in delay in processing the manuscript and it may be returned to the authors for correction before being submitted to a referee.

General

- Authors must submit three copies of the original manuscript typed in double line spacing. The journal is now produced electronically and revised manuscripts should be submitted as printed copy and on disk. A guide to submitting an article on disk will be sent when requesting a revision or on notification of an acceptance. Authors should not submit the original paper on disk.
- The names of the authors, with initials or one forename, should be followed by the name of the institution where the work was carried out. An indication of the position held by each author should be given in an accompanying letter to the Editors, and manuscripts should bear the name of one author to whom correspondence should be addressed. If available, a fax number and an e-mail address should be supplied.
- Identifying information should not be published in written descriptions, photographs, or pedigrees unless the information is essential for scientific purposes and the patient (or parent or guardian) gives written informed consent for publication; but patient data should never be altered or falsified in an attempt to attain anonymity. Informed consent should be obtained if there is any doubt. Masking the eyes in photographs of patients is inadequate protection of anonymity (for the full statement see the *BMJ*²).
- Authors should include the names and addresses of four experts whom the authors consider suitable to peer review their work.
- When submitting original manuscripts authors should send a copy of any of their other papers on a similar subject to assure the editors that there is no risk of duplicate publication.
- If requested, authors should produce the data upon which the manuscript is based for examination by the Editors.
- The number of authors should be kept to a minimum and should include only those who have made a contribution to the research: justification should be made for more than five authors. Acknowledgments should be limited to workers whose courtesy or assistance has extended beyond their paid work, and to supporting organisations.
- Sponsors of research must be declared.
- Authors should provide up to four keywords/phrases for the index.
- All measurements must be in SI units apart from blood pressure measurements, which should be in mmHg, and drugs in metric units.

- Abbreviations should be used rarely and should be preceded by the words in full before the first appearance.
- In the statistical analysis of data 95% confidence intervals should be used wherever appropriate.
- Any article may be submitted to outside peer review and for statistical assessment.
- No free offprints will be provided; reprints may be ordered when the proof is returned.

Original articles

- Papers should report original research of relevance to the understanding and practice of molecular pathology. They should be written in the standard form: abstract; introduction; results; and discussion.
- The journal uses a structured form of abstract in the interests of clarity. This should be short (no more than 250 words) and include four headings: *Aims*—the main purpose of the study; *Methods*—what was done, and with what material; *Results*—the most important results illustrated by numerical data but not p values; and *Conclusions*—the implications and relevance of the results.

Leaders/Editorials

- Leaders and Editorials are published by editorial invitation; unsolicited reviews or commentaries are unlikely to be accepted, though the Editors are always pleased to receive suggestions.

Short reports

- Single case reports of outstanding interest or clinical relevance, short technical notes, and brief investigative studies are welcomed and usually published in the form of a Short/Technical report.
- Length must not exceed 1500 words, including an unstructured abstract of less than 150 words, up to two figures or tables (or one of each) and up to 10 references. If more illustrations are required the text must be reduced accordingly.

Letters

- Letters must be typed in double line spacing, should normally be no more than 500 words, have no more than five references, and must be signed by all authors. Two copies should be provided.

Tables and illustrations

Tables should be presented separately in double line spacing without ruled lines; when presented on disk they should be in a separate file from the text.

- Letters and other marks which are to appear on the face of a photomicrograph should be made on a photocopy: they will be added in the Journal style in the editorial office when the manuscript is accepted.
- Legends for illustrations should be typed with double spacing on a separate sheet. The staining technique used should be stated. Magnifications should be given for electron micrographs but not for light micrographs except in cases where this is important.
- Photographs and photomicrographs should be on glossy paper for half tone reproduction. The printing process requires that prints are unmounted and unbacked, and of high quality, with full tonal scale. Illustrations that will not reproduce well will be returned and this may delay publication. Areas in which tissue does not appear ("background") should be as near white as possible. Three sets of prints must be supplied with each manuscript. Only salient features should be included to preserve detail.

- Colour reproduction of figures in papers is encouraged and is heavily subsidised by the Journal. Advice on costs and material to be submitted for colour work should be sought from the editorial office.
- If any tables or illustrations submitted have been published elsewhere, written consent to republication should be obtained by the author from the copyright holder (usually the publisher) and the authors. A copy of the letter giving consent must be included.

Descriptions of laboratory methods

- When a manufacturer's method is used in a study with a particular item of equipment or kit of reagents, the source of this method and reference to the scientific literature on which it was based should be given. Authors might consider it courteous to inform manufacturers that an article assessing their product has been submitted for publication.
- For quantitative methods, information on the sensitivity, precision, and accuracy in the hands of the authors should always be provided. When a well recognised method is used, these requirements could be met simply by providing the references to the methodology and discussing the performance in a recognised current quality assurance scheme. Modifications to methods that have not been previously published should be detailed in the text and supported by evidence of their efficacy.
- It is useful to indicate, either from personal observations or by reference, the working range of an assay and the normal reference range when it is used on samples from humans. When information is expressed as mean \pm 2SD, the distribution of the range (normal, skew, or logarithmic) should be stated.

References

- References must be numbered in the order they appear in the text and include all information (Vancouver style):
 - 1 Fletcher CDM, McKee H. Sarcomas - a clinicopathological guide with particular reference to cutaneous manifestations. I. Dermatofibrosarcoma protuberans, malignant fibrous histiocytoma and the epithelial sarcoma of Enzinger. *Clin Exp Dermatol* 1984;9:451-65.
 - 2 Washington JA. Conventional approaches to blood culture. In: Washington JA, ed. *The detection of septicemia*. West Palm Beach, Florida: CRP Press, 1978:41-87.
- References in the text should be identified by arabic numerals in brackets—for example, [1] [2].
- Abstracts, information from manuscripts not yet accepted, or personal communications may be cited only in the text and not included in the references. References are not checked by us; authors must verify references against the original documents before submitting the article.
 - 1 International Committee of Medical Journal Editors. Uniform requirements for manuscripts submitted to biomedical journals. *BMJ* 1991;302:338-41.
 - 2 International Committee of Medical Journal Editors. Protection of patients' rights to privacy. *BMJ* 1995;311:1272.

Manuscript checklist:

- Is there an abstract?
- Are the abbreviations spelt out?
- Are the measurements in SI units?
- Are the references in Vancouver style?